BRNS (Barinthus Biotherapeutics) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BRNS Barinthus Biotherapeutics PLC BRNS
47 GF Score
Price $0.62
GF Value $1.12
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

BRNS
47GF Score
Barinthus Biotherapeutics PLC BRNS
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Barinthus Biotherapeutics (BRNS) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of $0.62 is trading 44.9% below its estimated GF Value™ of $1.12. GuruFocus considers Barinthus Biotherapeutics to be Possible Value Trap.

Key valuation signals for BRNS:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $1.12 vs. price of $0.62 (44.9% below fair value)
  • GF Score™: 47/100 with 1 warning sign

No single metric tells the full story. See the BRNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
47GF Score

Get the complete analysis for BRNS

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.62
Price
$1.12
GF Value